Boston Scientific

Boston Scientific is a publicly traded company on the NYSE having a good stock performance record. The Boston Scientific Company is a fortune 500 stock listed company trading under the symbol BSX.

The company was co-founded by John E. Abele and Peter M. Nicholas in 1979. Boston Scientific has its headquarters in Natick, Massachusetts. Driven by the needs of the medical community for innovative products, the Company grew from revenues of approximately 2 million dollars in 1979 to more than 6.3 billion dollars in 2005. Jim Tobin joined Boston Scientific as President and Chief Executive Officer in 1999, bringing with him health care industry leadership and vision that will help the company build on its dramatic growth.

Boston Scientific Corporation reported financial results for the year and fourth quarter ended December 31, 2005. Net sales for 2005 were 6.283 billion dollars as compared to 5.624 billion dollars in 2004, an increase of 12 percent. Worldwide coronary stent system sales for 2005 were 2.69 billion dollars as compared to 2.35 billion dollars in 2004, an increase of 14 percent. Worldwide sales of TAXUS; paclitaxel-eluting coronary stent systems for 2005 were 2.56 billion dollars as compared to 2.14 billion dollars in 2004. U.S. sales of TAXUS stent systems for 2005 were 1.76 billion dollars as compared to 1.57 billion dollars in 2004.

Reported net income for 2005, including net special charges, was 628 million, or 0.75 per dollar diluted share, as compared to net income of 1.062 billion, or 1.24 per diluted share, for 2004. Reported results for 2005 included charges of 894 million, or 1.07 per share, which primarily related to: a litigation settlement with Medinol; purchased research and development; expenses related to certain retirement benefits; and costs that resulted from certain business optimization initiatives.

Boston Scientifics’ mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures. This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies that can reduce risk, trauma, cost, procedure time and the need for aftercare.